Expanding the use of T-DXd in metastatic HR-positive breast cancer: Where are we now? Editorial

  


Authors: Drago, J.; Modi, S.
Title: Expanding the use of T-DXd in metastatic HR-positive breast cancer: Where are we now?
Abstract: The DESTINY-Breast06 trial investigated earlier and broader use of trastuzumab deruxtecan in patients with metastatic hormone-receptor-positive breast cancer, and demonstrated improvements in progression-free survival over standard chemotherapy. These data provide a meaningful advance; however, this strategy might not be right for all patients, and careful consideration is recommended before blanket use. © Springer Nature Limited 2024.
Keywords: immunohistochemistry; signal transduction; drug approval; note; practice guideline; food and drug administration; cancer therapy; cancer resistance; patient care; disease control; metastatic breast cancer; drug use; molecular pathology; study design; pi3k/akt signaling; human; hormone receptor positive breast cancer; trastuzumab deruxtecan
Journal Title: Nature Reviews Clinical Oncology
Volume: 22
Issue: 1
ISSN: 1759-4774
Publisher: Nature Publishing Group  
Date Published: 2025-01-01
Start Page: 6
End Page: 7
Language: English
DOI: 10.1038/s41571-024-00963-2
PUBMED: 39506069
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85208575610&doi=10.1038%2fs41571-024-00963-2&partnerID=40&md5=98066872170cfd0c5b5735f302f4e7cd
Notes: Note -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Shanu Modi
    265 Modi
  2. Joshua Drago
    27 Drago
Related MSK Work